L3VLUP
ProSign in

HAE · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HAELLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HAE
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterHAELLY
Q3 202016 holders, $1.3bn33 holders, $14.1bn
Q4 202011 holders, $1.6bn29 holders, $17.3bn
Q1 202111 holders, $1.5bn24 holders, $23.0bn
Q2 20218 holders, $741m24 holders, $27.8bn
Q3 202111 holders, $843m31 holders, $29.9bn
Q4 202110 holders, $649m31 holders, $34.7bn
Q1 20229 holders, $1.0bn24 holders, $35.3bn
Q2 20228 holders, $1.1bn33 holders, $42.7bn
Q3 20228 holders, $1.3bn31 holders, $43.4bn
Q4 20228 holders, $1.2bn31 holders, $46.6bn
Q1 20237 holders, $1.2bn33 holders, $44.3bn
Q2 20237 holders, $1.2bn37 holders, $59.6bn
Q3 20237 holders, $1.2bn44 holders, $67.6bn
Q4 20236 holders, $1.2bn45 holders, $73.6bn
Q1 20246 holders, $1.3bn41 holders, $95.3bn
Q2 20245 holders, $1.2bn43 holders, $110bn
Q3 20245 holders, $1.0bn45 holders, $107bn
Q4 20245 holders, $986m46 holders, $93.9bn
Q1 20259 holders, $622m42 holders, $98.4bn
Q2 20259 holders, $666m43 holders, $93.2bn
Q3 20255 holders, $323m39 holders, $86.7bn
Q4 20258 holders, $894m41 holders, $123bn
Q1 20263 holders, $464m39 holders, $106bn
Q2 20266 holders, $619m44 holders, $132bn
HAE

Haemonetics Corp Mass

Holders
6
Reported value
$619m
Buyers
12
Sellers
18

Breadth -6 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HAE (1)

Verition Fund Management LLC

Only LLY (39)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, and 14 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →